Background Treatment modalities for choroidal neovascularization due to ocular toxoplasmosis include laser photocoagulation, surgery, corticosteroids, and verteporfin therapy. Intravitreal injection of bevacizumab in the treatment of choroidal neovascularization due to other conditions appears to be an effective and safe therapeutic option. Case reports We report two young patients with choroidal neovascularization secondary to ocular toxoplasmosis who received a single intravitreal injection of bevacizumab as primary or rescue therapy. After a follow-up of 12 and 10 months, respectively, visual acuity improved, and features of active neovascularization resolved with no recurrence. No adverse events were recorded. Conclusion Intravitreal injection of bevacizumab appears to be an effective and safe treatment modality in patients with choroidal neovascularization secondary to ocular toxoplasmosis. Further evaluation with a longer follow-up period is needed to confirm these findings.
This is a preview of subscription content, log in to check access.
Adan A, Mateo C, Wolley-Dod C (2003) Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis. Am J Ophthalmol 135:386–387PubMedCrossRefGoogle Scholar
Wirthlin R, Song A, Song J, Rosenfeld PJ (2006) Verteporfin photodynamic therapy of choroidal neovascularization secondary to ocular toxoplasmosis. Arch Ophthalmol 124:741–743PubMedCrossRefGoogle Scholar
Perentes Y, Van Tran T, Sickenberg M, Herbort CP (2005) Subretinal neovascular membranes complicating uveitis: frequency, treatments and visual outcome. Ocul Immunol Inflamm 13:219–224PubMedCrossRefGoogle Scholar
Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372PubMedCrossRefGoogle Scholar
Laud K, Spaide RF, Freund KB et al (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960–963PubMedCrossRefGoogle Scholar
Teixeira A, Moraes N, Farah ME, Bonomo PP (2006) Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. Acta Ophthalmol Scand 84:835–836PubMedCrossRefGoogle Scholar
Kwak N, Okamoto N, Wood JM, Campochiaro PA (2000) VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158–3164PubMedGoogle Scholar
Perentes Y, Chan CC, Bovey E, Uffer S, Herbort CP (2002) Massive vascular endothelial growth factor (VEGF) expression in Eales’ disease. Klin Monatsbl Augenheilk 219:11–14CrossRefGoogle Scholar
Shahar J, Avery RL, Heilweil G et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262–269PubMedCrossRefGoogle Scholar
Adan A, Mateo C, Navarro R et al (2007) Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 27:1180–1186PubMedGoogle Scholar